DENVER, Sept. 08, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – For NeOnc Technologies Holdings (NASDAQ: NTHI), the Phase 2a question has been answered. Now comes the question that could matter even more to the market: What will the FDA do with the data?
On August 12, NeOnc reported positive topline results from the NEO100-01 Phase 2a study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The company reported six-month progression-free survival of 48.9%, more than double the study's prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was reported at 26.09 months, while 86.7% of patients were alive at six months. Five of the 24 patients remained on treatment, including one patient whose partial response continued beyond 114 days.
That would already be enough to put a clinical-stage oncology company on the radar. But NeOnc immediately identified its next potential catalyst: a planned Type B meeting with the U.S. Food and Drug Administration to discuss a potential registrational pathway for NEO100. CEO Amir Heshmatpour called the results “an important milestone for NeOnc” and said the company's priority was to engage with the FDA and align on the most efficient path toward a registrational study.
The underlying proposition is also distinctive. NEO100 is an intranasal formulation of purified perillyl alcohol designed around nose-to-brain delivery, an approach intended to address one of the central problems in CNS oncology: getting therapeutics into the brain. The company has positioned NEO100 as a potential treatment for aggressive gliomas in a setting where treatment options remain limited.
The market now has a defined catalyst chain rather than a single binary data event: Phase 2a success → FDA interaction → potential registrational design → additional clinical validation, and has moved the conversation from “Can NEO100 produce a meaningful signal?” toward the much more consequential question of how regulators might want that signal developed.
The broader pipeline gives investors another reason to watch. In June, NeOnc received UAE IND authorization for NEO100 covering three adult programs ranging from Phase 1 through Phase 2, as well as pediatric development. NEO212, the company's oral perillyl alcohol-temozolomide conjugate, also received UAE IND clearance after completing Phase 1 dose escalation and establishing a recommended Phase 2 dose of 610 mg.
There is also an unusual insider-activity angle. SEC-filed information shows director Thomas Chen purchased 33,787 shares at a weighted average $3.8477 on August 14 and another 2,472 shares at $4.0445 on August 17. Additional purchases by Amir Heshmatpour were also reported in August. Insider buying does not predict clinical success, but it adds another data point to the market's rapidly changing perception of NTHI.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.